Stocks›Healthcare›EDIT

EDIT

Editas Medicine, Inc.

NasdaqResearch view

Editas Medicine, Inc. operates in the Biological Products, (No Diagnostic Substances) industry.

$2.75+0.73%

Oct 7 close · 1D EOD · Databento

HealthcareBiological Products, (No Diagnostic Substances)Small-capSEC EDGAR FY 2025-12-31

On the Wire · latest 1

All stories →

Oct 8 · GlobeNewswireEditas wins clearance to start first-in-human EDIT-401 trialEditas Medicine received approval to begin dosing patients in a Phase 1/2 trial of EDIT-401 for hyperlipidemia. The study creates an early clinical milestone for a company whose next valuation test will depend on human safety and LDL-C results.

On the Wire · latest 1

All stories →

Oct 8 · GlobeNewswireEditas wins clearance to start first-in-human EDIT-401 trialEditas Medicine received approval to begin dosing patients in a Phase 1/2 trial of EDIT-401 for hyperlipidemia. The study creates an early clinical milestone for a company whose next valuation test will depend on human safety and LDL-C results.

What happened

Daily closes · dots are Wire stories

What’s next

Expected around early November, going by its own filing history. The company has not announced a date yet. Its matching report came Nov 10, 2025 and Nov 4, 2024, after the close.

Last report

Aug 5, 2026+5.45%

after the close

Last 4, next close

median 3.74% either way

up 4 of 4

Every report since 2023 →Earnings calendar →

DateEventSourceNext close

Aug 5Earnings release, after the close · 8-KSEC EDGARSEC EDGAR ↗+5.45%

Next close = the first close after the event against the close before it. Prior-session closes only; not a call, not advice.

What happened · big days

19 big days in a year, and what we hold on each

A big day is a close more than 9.39% from the one before, three times EDIT’s median day (3.13%). On 0 of the 19, its peer group moved the same way at least half as far. We show what we hold. We never name a cause.

every other trading daya big day, numbered in the list below±9.39%Hover a bar for its day. Click a big day to open it.

Shaded: since our stories began, Jun 10. Tap a bar for its day.

#DayEDITWhat we hold that dayGroup (median of 4) · each

1 Oct 15, 2025+13.09%
Before our storiesgroup +0.5%, did not move with it
1Oct 15, 2025+13.09%
Before our stories
+0.5% did not move with itMRNA +5.6 · AMGN +1.2 · GILD −0.1 · BIIB −1.1
2 Oct 20, 2025+9.81%
Before our storiesgroup +2.0%, did not move with it
2Oct 20, 2025+9.81%
Before our stories
+2.0% did not move with itMRNA +4.7 · BIIB +2.5 · AMGN +1.5 · GILD +0.2
3 Oct 27, 2025−12.63%
Before our storiesgroup −0.3%, did not move with it
3Oct 27, 2025−12.63%
Before our stories
−0.3% did not move with itGILD −0.4 · MRNA −0.3 · AMGN −0.2 · BIIB +0.4
4 Dec 3, 2025+12.09%
Before our storiesgroup +1.5%, did not move with it
4Dec 3, 2025+12.09%
Before our stories
+1.5% did not move with itMRNA +4.7 · AMGN +2.1 · GILD +0.9 · BIIB +0.3
5 Jan 22, 2026+12.26%
Before our storiesgroup +1.3%, did not move with it
5Jan 22, 2026+12.26%
Before our stories
+1.3% did not move with itMRNA +4.1 · GILD +1.6 · AMGN +1.0 · BIIB +0.7
6 Feb 5, 2026−14.62%
Before our storiesgroup +0.2%, did not move with it
6Feb 5, 2026−14.62%
Before our stories
+0.2% did not move with itMRNA −4.4 · BIIB −0.1 · AMGN +0.4 · GILD +2.1
7 Feb 24, 2026+11.64%
Before our storiesgroup −0.1%, did not move with it
7Feb 24, 2026+11.64%
Before our stories
−0.1% did not move with itAMGN +0.9 · MRNA +0.5 · BIIB −0.6 · GILD −1.5
8 Mar 5, 2026−13.47%
Before our storiesgroup −2.6%, did not move with it
8Mar 5, 2026−13.47%
Before our stories
−2.6% did not move with itMRNA −6.9 · AMGN −3.1 · GILD −2.1 · BIIB −1.0
9 Mar 9, 2026+16.00%
Resultsgroup +1.9%, did not move with it
9Mar 9, 2026+16.00%
ResultsFirst close after the Mar 9 results filing
+1.9% did not move with itMRNA +6.1 · AMGN +2.0 · GILD +1.9 · BIIB +1.8
10 Mar 10, 2026+13.79%
Before our storiesgroup −0.2%, did not move with it
10Mar 10, 2026+13.79%
Before our stories
−0.2% did not move with itGILD +1.3 · BIIB +0.1 · AMGN −0.4 · MRNA −1.4
11 Mar 31, 2026+10.76%
Before our storiesgroup +1.5%, did not move with it
11Mar 31, 2026+10.76%
Before our stories
+1.5% did not move with itMRNA +5.3 · GILD +2.2 · AMGN +0.8 · BIIB −2.3
12 May 26, 2026+11.59%
Before our storiesgroup −0.4%, did not move with it
12May 26, 2026+11.59%
Before our stories
−0.4% did not move with itMRNA +0.3 · BIIB −0.3 · GILD −0.5 · AMGN −1.0
13 May 27, 2026+15.91%
Before our storiesgroup +0.6%, did not move with it
13May 27, 2026+15.91%
Before our stories
+0.6% did not move with itBIIB +2.0 · MRNA +1.2 · AMGN +0.0 · GILD −0.0
14 Jun 2, 2026−15.57%
Before our storiesgroup −1.3%, did not move with it
14Jun 2, 2026−15.57%
Before our stories
−1.3% did not move with itGILD −2.7 · BIIB −1.8 · MRNA −0.9 · AMGN −0.3
15 Jun 29, 2026+12.28%
Nothing on EDITgroup +0.5%, did not move with it
15Jun 29, 2026+12.28%
Nothing on EDITNo EDIT story, brief or results filing in our record that day
+0.5% did not move with itMRNA +3.6 · AMGN +0.6 · BIIB +0.3 · GILD −1.2
16 Jul 2, 2026+11.28%
Nothing on EDITgroup +3.9%, did not move with it
16Jul 2, 2026+11.28%
Nothing on EDITNo EDIT story, brief or results filing in our record that day
+3.9% did not move with itMRNA +10.0 · GILD +4.2 · AMGN +3.5 · BIIB +3.0
17 Jul 9, 2026−10.08%
Nothing on EDITgroup −0.7%, did not move with it
17Jul 9, 2026−10.08%
Nothing on EDITNo EDIT story, brief or results filing in our record that day
−0.7% did not move with itAMGN −1.2 · GILD −0.7 · BIIB −0.7 · MRNA +3.7
18 Aug 19, 2026+12.85%
Nothing on EDITgroup +4.1%, did not move with it
18Aug 19, 2026+12.85%
Nothing on EDITNo EDIT story, brief or results filing in our record that day
+4.1% did not move with itMRNA +177.0 · BIIB +4.2 · AMGN +4.0 · GILD +2.9
19 Aug 20, 2026−9.54%
Nothing on EDITgroup −3.0%, did not move with it
19Aug 20, 2026−9.54%
Nothing on EDITNo EDIT story, brief or results filing in our record that day
−3.0% did not move with itMRNA −23.6 · BIIB −3.3 · GILD −2.8 · AMGN −1.9

A story on the same day is not a cause, and a group move is not proof either. Group: the median of AMGN, GILD, MRNA and BIIB that day, the largest companies in EDIT’s SEC industry; “moved with EDIT” means the same direction and at least half the size.

What’s next · results

Before the next report: what the first day after the last four did

Six trading days after each results filing (SEC 8-K, Item 2.02). Day 1 is the first close after each filing: the next day’s for a filing after the close, the same day’s otherwise. 3 of 4 times, day 6 ended on the same side as day 1.

Reported Nov 10, 2025

day 1+2.02%day 6+4.45%

Reported Mar 9, 2026

day 1+16.00%day 6+27.00%

Reported May 5, 2026

day 1+1.33%day 6−2.33%

Reported Aug 5, 2026

day 1+5.45%day 6+2.18%

Next report: expected early NovemberEstimated from the dates of its last four results filings. Not announced. Since the Aug 5 report: 0.00%. Four reports is a small sample.

Every report since 2023 →

Each line is EDIT’s close against its close before the filing, on licensed end-of-day closes. What happened after each report, not a forecast; a move on the day is not a cause.

The numbers · FY2025, filed

SEC EDGAR

Market cap$422M

Revenue$40.5M+25.40%

Net income$-160.1M

EPS, diluted$-1.80+37.50%

Operating margin-394.9%

Return on equity-586.6%

Debt / equity2.15

All filed figures

Snapshot

SEC EDGAR · FY 2025-12-31

SectorHealthcare

Market Cap$422.3M

Enterprise Value$331.6M

Income$-160.1M

Sales$40.5M

Book/sh$0.18

Cash/sh$0.97

Dividend TTM—

Payout—

Employees—

IPO—

Quick Ratio—

Current Ratio3.54

Debt/Eq2.15

EPS (ttm)$-1.80

EPS this Y37.5%

EPS past 3/5Y—

Sales past 3/5Y27.1%

EPS Y/Y TTM37.5%

Sales Y/Y TTM25.4%

Shs Outstand153.58M

ROA-85.8%

ROE-586.6%

ROIC—

Gross Margin—

Oper. Margin-394.9%

Profit Margin-395.0%

Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.

Revenue by fiscal year

$25.5M

FY21

$19.7M

FY22

$78.1M

FY23

$32.3M

FY24

$40.5M

FY25

Operating leverage — margins

GrossOperatingNet

Financials, annual · income and cash flowSEC EDGAR · open ▸

Financials — annual

SEC EDGAR · last 5 FY · tap a row to explain it

USD	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$25.5M	$19.7M	$78.1M	$32.3M	$40.5M
Gross Profit	—	—	—	—	—
Operating Income	$-193.1M	$-225.9M	$-169.2M	$-251.2M	$-160.0M
Net Income	$-192.5M	$-220.4M	$-153.2M	$-237.1M	$-160.1M
Diluted EPS	$-2.85	$-3.21	$-2.02	$-2.88	$-1.80
Operating Cash Flow	$-163.8M	$-177.3M	$-132.2M	$-210.3M	$-165.2M
Free Cash Flow	$-171.8M	$-181.5M	$-136.9M	$-219.1M	$-165.8M

Same industry

EDIT against four biotech peers, a year at 100

EDIT is down 26.1% in a year. Moderna is up 7.3 times, Biogen is up 51.6%, Amgen 42.4% and Gilead Sciences 25.3%. All four did more. Weekly closes, Oct 10, 2025 = 100, on a log scale so a 7.3-fold rise and a 26.1% fall both read honestly.

Share this chart

EDIT −26.1%. Moderna ×7.3, Biogen +51.6%, Amgen +42.4%, Gilead Sciences +25.3%. Weekly closes, Oct 10, 2025 = 100, log scale.

Share this chart

End-of-day closes (Databento EOD), the last close of each week. The four peers are the largest US-listed companies by market value in EDIT’s SEC industry (Biological Products, (No Diagnostic Substances)) with a year of closes. It shows what the closes did; a move here is not a cause, a forecast or a call.

Same industry

In the screener →

AMGN$223.3B GILD$182.1B MRNA$78.4B BIIB$32.8B NBIX$14.6B EXEL$14.5B HALO$12.6B TECH$11.4B

Follow the news. Track the move.

EDIT story timeline

Company updates and connected market context, with the dated price move attached.

Stories

Direct

EDIT direct/Consumer

Oct 8

Editas wins clearance to start first-in-human EDIT-401 trial

Editas Medicine received approval to begin dosing patients in a Phase 1/2 trial of EDIT-401 for hyperlipidemia. The study creates an early clinical milestone for a company whose next valuation test will depend on human safety and LDL-C results.

Price history unavailable

GlobeNewswire · 8h ago

View both sides →